Advisory Committee Review Expected Prior To Tysabri Market Re-Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan expect Tysabri will be subject to an FDA advisory committee review before the multiple sclerosis therapy is allowed back on the market